BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
The Healthcare M&A Wave
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
3 Biotech Stocks That Could Benefit from the Patent Cliff
Colossal’s Ben Lamm Says Invasive Species Is a $5.4 Trillion Problem. Here’s His Solution
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.
Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares
Beam Therapeutics (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 11,810 Shares
SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026
BEAM Eyes Global Expansion of AATD Study After Strong Early Data
Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript
Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of “Moderate Buy” from Analysts
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
Beam Therapeutics: Great Potential, But Patience Is Needed
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
What's Going On With Beam Therapeutics Stock?
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
Cathie Wood Buys COIN After 16% Jump
Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933
Christine Bellon Sells 1,371 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 18,629 Shares of Stock
SG Americas Securities LLC Purchases 36,004 Shares of Beam Therapeutics Inc. $BEAM
Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Beam Therapeutics: Pivoting From Platform To Execution Stage
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises